HPV16+ Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 10+ Key Companies | DelveInsight

DelveInsight's "HPV16+ Cancer Pipeline Insight 2026" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in the HPV16+ Cancer pipeline landscape. It covers the HPV16+ Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HPV16+ Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the HPV16+ Cancer Pipeline? @ HPV16+ Cancer Pipeline Outlook Report- https://www.delveinsight.com/sample-request/human-papillomavirus-16-positive-hpv16-cancers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the HPV16+ Cancer Pipeline Report
• On April 15, 2026, BioNTech SE initiated a Phase II/III study Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1
• On April 06, 2026, PDS Biotechnology Corp. conducted a Phase 3 study that is randomized 1:1, controlled, and open label to evaluate PDS0101 (Versamune + HPVMix) in combination with pembrolizumab vs. pembrolizumab monotherapy as first-line treatment in patients with unresectable recurrent or metastatic HPV16-positive HNSCC expressing programmed cell death ligand-1 (PD-L1) with combined positive score (CPS) ≥1.
• DelveInsight's HPV16+ Cancer Pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for HPV16+ Cancer treatment.
• The leading HPV16+ Cancer Companies, such as ISA Pharmaceuticals, Cue Biopharma, Genexine, Vaccibody AS, PDS Biotechnology, BlueSky Immunotherapies GmbH and others.
• Promising HPV16+ Cancer Therapies such as ISA 101, Nivolumab, TG4001, Avelumab, VGX-3100, ISA101/ISA101b, and others.

Want to know which companies are leading innovation in HPV16+ Cancer? @ HPV16+ Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/human-papillomavirus-16-positive-hpv16-cancers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The HPV16+ Cancer Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The HPV16+ Cancer Pipeline Report also highlights the unmet needs with respect to the HPV16+ Cancer.

HPV16+ Cancer Overview
Human papillomavirus 16 (HPV16) is one of the high-risk strains of HPV, primarily linked to various cancers, including cervical, oropharyngeal, anal, and cancers. HPV16 is a DNA virus that infects epithelial cells, and it is transmitted through sexual contact. Persistent infection with HPV16 can lead to the development of malignant tumors, making it a significant public health concern. HPV16-positive cancers are more common in both men and women and have been increasing in prevalence, particularly oropharyngeal cancers. The signs and symptoms of HPV16-positive cancers depend on the site of infection. For cervical cancer, early stages often present no symptoms, but advanced stages may include irregular bleeding, pelvic pain, and discharge.

HPV16+ Cancer Emerging Drugs Profile
• ISA101b: ISA Pharmaceuticals
ISA101b consists of 12 synthetic long peptides derived from the E6 and E7 oncogenic proteins of the HPV 16 virus, a strain responsible for over 50% of human cervical cancers and cervical intra-epithelial neoplasias, more than 85% of HPV-positive head and neck cancers, and similar substantial percentages of other premalignant and malignant HPV-induced lesions (such as VIN, vulvar cancer, AIN and anal cancer). It is currently administered either subcutaneously or intradermally. ISA101 has completed a Phase II trial in vulvar intra-epithelial neoplasia, establishing clinical proof-of-concept. In cervical cancer, ISA101 has successfully completed a company-sponsored Phase I/II trial and has entered into further clinical development in collaboration with Regeneron. The alliance aims to develop and advance ISA101 in combination with cemiplimab (Libtayo®), a PD-1 (programmed cell death protein 1) antibody currently under review by EMA and initially approved by the U.S. Food and Drug Administration in September 2018 under the brand name Libtayo® as monotherapy for patients with advanced cutaneous squamous cell carcinoma. Currently, the drug is in Phase II stage of its development for the treatment of HPV16-Positive Oropharyngeal Cancer (OPC).

• CUE-101: Cue Biopharma
The CUE-100 series of biologics have the potential to improve efficacy and reduce the severe toxicities associated with non-specific IL-2 cancer immunotherapies. They are engineered to selectively engage and modulate tumor-specific immune T cells by taking advantage of the specificity already existing in nature, and avoid toxicities associated with indiscriminate immune activation. CUE-101, has already demonstrated clinical activity and favorable tolerability as a monotherapy in a Phase I trial in patients with human papilloma virus (HPV16+) recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). This validates the clinical applicability of our technology platforms and therapeutic potential of our advanced pipeline of biologics for the treatment of cancer. Currently, the drug is in Phase II stage of its development for the treatment of Oropharyngeal Squamous Cell Carcinoma.

If you're tracking ongoing HPV16+ Cancer Clinical trials, this press release is a must-read @ HPV16+ Cancer Treatment Drugs- https://www.delveinsight.com/sample-request/human-papillomavirus-16-positive-hpv16-cancers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The HPV16+ Cancer Pipeline report provides insights into:-
• The report provides detailed insights about companies that are developing therapies for the treatment of HPV16+ Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HPV16+ Cancer Treatment.
• HPV16+ Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• HPV16+ Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HPV16+ Cancer market.

HPV16+ Cancer Companies
ISA Pharmaceuticals, Cue Biopharma, Genexine, Vaccibody AS, PDS Biotechnology, BlueSky Immunotherapies GmbH and others.

HPV16+ Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

HPV16+ Cancer Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the HPV16+ Cancer Pipeline Report @ HPV16+ Cancer Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/human-papillomavirus-16-positive-hpv16-cancers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the HPV16+ Cancer Pipeline Report
• Coverage- Global
• HPV16+ Cancer Companies- ISA Pharmaceuticals, Cue Biopharma, Genexine, Vaccibody AS, PDS Biotechnology, BlueSky Immunotherapies GmbH and others.
• HPV16+ Cancer Therapies- ISA 101, Nivolumab, TG4001, Avelumab, VGX-3100, ISA101/ISA101b and others.
• HPV16+ Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HPV16+ Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what's next for the HPV16+ Cancer Treatment landscape in this detailed analysis @ HPV16+ Cancer Emerging Drugs and Major Players- https://www.delveinsight.com/sample-request/human-papillomavirus-16-positive-hpv16-cancers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. HPV16+ Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HPV16+ Cancer - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. HPV16+ Cancer Collaboration Deals
9. Mid Stage Products (Phase II)
10. ISA101b: ISA Pharmaceuticals
11. Drug profiles in the detailed report.....
12. Early Stage Products (Phase I)
13. Drug profiles in the detailed report.....
14. Pre-clinical and Discovery Stage Products
15. Drug profiles in the detailed report.....
16. Inactive Products
17. HPV16+ Cancer Key Companies
18. HPV16+ Cancer Key Products
19. HPV16+ Cancer- Unmet Needs
20. HPV16+ Cancer- Market Drivers and Barriers
21. HPV16+ Cancer- Future Perspectives and Conclusion
22. HPV16+ Cancer Analyst Views
23. HPV16+ Cancer Key Companies
24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.